Otsuka’s ADHD Contender Hits Mark In Phase III
Validation Of $250m Acquisition
Executive Summary
Otsuka's novel ADHD therapy moves closer to a potential filing after meeting its endpoint in two Phase III trials, validating a past acquisition and further bolstering the Japanese firm's CNS prospects.